Study on the prevention of VTE in patients with acute respiratory failure by low molecular weight heparin

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054277

Enrollment

Unknown

Registered

2021-12-12

Start date

2021-12-12

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory failure

Interventions

low-dose group:Nadroparin injection 0.3ml ih qd

mid-dose group:Nadroparin injection 0.3ml ih q12h

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients with acute respiratory failure (arterial blood gas analysis in the state of inhaling room air: PaO2 = 50mmHg); 2. Aged 18-85 years; 3. The weight is more than 40kg.

Exclusion criteria

Exclusion criteria: 1. The main diagnosis is non-respiratory diseases; 2. Participated in other clinical investigators within 3 months before participating in this study; 3. The life expectancy of combined malignant tumor is less than 3 months; 4. Long-term ICU patients: stay in ICU for more than 4 weeks; 5. Ventilator-dependent patients: mechanical ventilation for more than 4 weeks; 6. Combined pregnancy; 7. It is found that VTE requires anticoagulation or ECMO; 8. Anticoagulation contraindications; 9. Allergy to low molecular weight heparin; 10. Heparin-related thrombocytopenia.

Design outcomes

Primary

Measure	Time frame
Incidence of VTE;	—

Secondary

Measure	Time frame
Bleeding events;Length of stay;Incidence of death;	—

Countries

China

Contacts

Public ContactJiang Jinjun

jiang.jinjun@zs-hospital.sh.cn+86 13564328315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026